Novartis shares experienced a significant decline following disappointing results from the del desiran drug trial, impacting investor confidence.
Read More
The Geo Chronicle
Your Window to World Affairs
Novartis Cholesterol Drug Setback Shifts Focus to Amgen and Eli Lilly
Novartis faces a setback in its cholesterol drug development, raising the stakes for Amgen and Eli Lilly in treating Lp(a)…
Read MoreYOU MAY HAVE MISSED
